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Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) by overexpression of the transcription factors OCT4,
SOX2, KLF4, and c-Myc holds great promise for the development of personalized cell replacement therapies. In an attempt to
minimize the risk of chromosomal disruption and to simplify reprogramming, several studies demonstrated that a reduced set of
reprogramming factors is sufficient to generate iPSC. We recently showed that a reduction of reprogramming factors in murine
cells not only reduces reprogramming efficiency but also may worsen subsequent differentiation. To prove whether this is also
true for human cells, we compared the efficiency of neuronal differentiation of iPSC generated from fetal human neural stem
cells with either one (OCT4; hiPSC
1F-NSC) or two (OCT4, KLF4; hiPSC2F-NSC) reprogramming factors with iPSC produced from
human fibroblasts using three (hiPSC
3F-FIB) or four reprogramming factors (hiPSC4F-FIB). After four weeks of coculture with PA6
stromal cells, neuronal differentiation of hiPSC
1F-NSC and hiPSC2F-NSC was as efficient as iPSC3F-FIB or iPSC4F-FIB. We conclude
that a reduction of reprogramming factors in human cells does reduce reprogramming efficiency but does not alter subsequent
differentiation into neural lineages. This is of importance for the development of future application of iPSC in cell replacement
therapies.
1. Introduction
Reprogramming of somatic cells into induced pluripotent
stem cells (iPSCs), which initially was achieved in mouse and
human fibroblasts by ectopic expression of four transcription
factors, OCT4 (also called OCT3/4 or Pou5f1), SOX2, KLF4,
and c-Myc [1–6], is nowadays widely considered as a major
breakthrough for regenerative medicine and has become a
ground-breaking and competitive field of research during
recent years. Their therapeutic potential was exemplarily
shown in animal models of Parkinson’s disease (PD) [7],
sickle cell anemia [8], acute myocardial infarction [9], and
diabetes [10], giving hope for future clinical applications in
personalized cell repair strategies.
Originally, induction of pluripotency in somatic cells
was achieved by forced expression of OCT4, SOX2, KLF4,
and c-Myc via retroviral integration [1–6]. These procedures
harbour some limitations for future clinical applications as
reactivation or sustained expression of reprogramming trans-
genes may result in tumor formation [4], induce dysplasia
[11, 12], and also impair the developmental potency of iPSC
by altering the expression of transcription factors responsible
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for pluripotency [13, 14]. Additionally, remaining transgene
expression may interfere with downstream differentiation
experiments in vitro.Therefore, many strategies were used to
generate iPSC without retroviral integrations including the
use of nonintegrating adenoviruses [15], oriP/EBNA1-based
episomal vectors [16], PiggyBac transposon systems [17, 18],
transient transfection with reprogramming plasmids [19],
Cre recombinase excisable viruses [20], and recombinant
proteins [21, 22] and with synthetic RNA [23]. However,
reprogramming with recombinant proteins is still of very
low efficiency and, thus, needs further optimization before
being available for routine use for the generation of iPSC for
research and translational medicine.
Another strategy to minimize the risk for chromosomal
disruption is to reduce the number of reprogramming fac-
tors. Indeed, generation of iPSC from mouse and human
fibroblasts is possible without the use of c-Myc, although at
a lower efficiency [24, 25]. Reprogramming with only OCT4
and KLF4 has been successfully achieved in adult mouse
neural stem cells (NSCs) [26–28]. Furthermore, iPSCs were
successfully generated from human fibroblasts using OCT4
and SOX2 [29] and from human NSC using OCT4 and KLF4
[30]. Finally, adult mouse and fetal human NSCs can also be
directly reprogrammed to pluripotency by OCT4 alone [31,
32]. OCT4 alone seems to be able to induce pluripotency in
primary somatic cells when combined with small molecules
[33].
We recently demonstrated that neuronal differentiation is
significantly less effective in one- and two-factor iPSC from
murine adult NSCs suggesting limitations for the strategy
of factor reduction to minimize the risk for chromosomal
disruption as prerequisite for therapeutic use [34]. Since
species differences may be responsible for this issue, we here
investigate the neuronal differentiation behaviour of factor-
reduced iPSC derived from human NSC. Our data could
have important consequences for future clinical applications
of factor-reduced iPSC, which will depend on an effective
output of differentiated cells.
2. Methods
2.1. Derivation of iPSCs. For this comparative study, we
used iPSCs derived from fetal human NSCs [32] and iPSCs
produced from adult human fibroblasts [35]. iPSCs from
fetal human NSCs were produced by retroviral introduction
of either one (OCT4; iPSC
1F-NSC) or two (OCT4, KLF4;
iPSC
2F-NSC) reprogramming factors [28, 31, 32]. iPSCs from
adult human fibroblasts were generated by retroviral intro-
duction of three (OCT4, KLF4, and SOX2; iPSC
3F-FIB) or all
four (OCT4,KLF4, SOX2, and c-Myc; iPSC
4F-FIB) reprogram-
ming factors as published in [35, 36]. iPSCs were cultured
in colonies on feeder layers of mitotically inactivated mouse
embryonic fibroblasts using standard procedures [32, 35].
2.2. Neuronal Differentiation of iPSCs. Neuronal differenti-
ation of iPSCs was induced by coculture with PA6 stromal
cells, which has been shown to promote neural induction
by stromal cell-derived inducing activity (SDIA) and to
generate high proportions of midbrain specific dopaminergic
neurons from ESC and iPSC [34, 37]. Freshly passaged
colonies were plated on confluent layers of PA6 cells, which
had been propagated in 𝛼-Minimum Essential Medium
(𝛼MEM; Invitrogen) supplemented with 10% FCS (Sigma-
Aldrich), 100U/mL penicillin, and 100 𝜇g/mL streptomycin
(Invitrogen) and had been seeded one day before on 0.1%
gelatine-coated 4-well tissue culture plates (NalgeNunc Inter-
national, Rochester, NY, USA) with coverslips. After seeding,
iPSCs were cultured on the PA6 cells in Glasgow Minimum
Essential Medium (GMEM; Invitrogen) supplemented with
10% Knockout Serum Replacement (Invitrogen), 2mM L-
glutamine (Invitrogen), 1mM sodium pyruvate (Invitro-
gen), 1x nonessential amino acids (Invitrogen), 0.1mM 𝛽-
mercaptoethanol (Sigma-Aldrich), 100U/mL penicillin, and
100 𝜇g/mL streptomycin (Invitrogen). Medium was changed
on day 4 and every other day following that. On day 14,
medium was changed to DMEM supplemented with 1% N-2
(Invitrogen), 2mM L-glutamine (Invitrogen), 1mM sodium
pyruvate (Invitrogen), 0.1mM nonessential amino acids
(Invitrogen), 0.1mM 2-mercaptoethanol (Sigma-Aldrich),
100U/mL penicillin, and 100𝜇g/mL streptomycin (Invitro-
gen), and medium change was performed every second day
thereafter. After 3-4 weeks, cells on coverslips were rinsed
with phosphate-buffered saline (PBS; Invitrogen), fixed for
30 seconds with formalin-free fixative (Accustain; Sigma-
Aldrich), and afterwards rinsed twice with PBS.
2.3. Immunocytochemistry after Neural Differentiation. Stan-
dard procedures were used [38]. In brief, fixed samples were
incubated for 2 hours with blocking buffer consisting of
PBS, 3% normal donkey serum (Jackson ImmunoResearch,
Suffolk, UK), and 0.1% Triton X-100 (Serva, Heidelberg,
Germany) and exposed to primary antibodies in blocking
buffer overnight at 4∘C. After incubation with primary
antibodies, cells were rinsed four times with PBS and sub-
sequently exposed to fluorescent-labeled Alexa Fluor (Invit-
rogen) secondary antibodies for 1 hour at room temperature
(1 : 500). After rinsing in PBS, coverslips were counterstained
with Hoechst 33342 (7.5 𝜇g/mL; Invitrogen), mounted onto
slides in Vectashield mounting medium (Vector Laborato-
ries, Burlingame, CA, USA), and sealed with nail polish.
Microscopic analysis was performed using an inverted flu-
orescent microscope (DMIRE2, Leica Microsystems). On
each coverslip, all colonies containing cells with a positive
staining for a specific marker were counted and put into
relation to the total number of colonies detected by Hoechst
counterstaining.The following primary antibodies were used:
rabbit anti-TUJ1 (1 : 2000; Covance; Princeton, NJ, USA),
mouse anti-microtubule-associated protein 2 (anti-MAP2;
1 : 500; BD Pharmingen, Franklin Lakes, NJ, USA), rabbit
anti-tyrosine hydroxylase (anti-TH; 1 : 500; Pel-Freez, Rogers,
AR, USA), chicken anti-glial fibrillary acidic protein (anti-
GFAP; 1 : 1000; Abcam, Cambridge, MA, USA), and mouse
anti-galactosylceramidase (anti-GALC; 1 : 750; Millipore).
2.4. Statistical Analysis. Either two-sided unpaired 𝑡-test or
one-way analysis of variance (ANOVA test) with Bonferroni
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Figure 1: Comparison of neuroectodermal differentiation potential of human factor-reduced iPSCs. (a) Representative images of
TUJ1+, GFAP+, GALC+, MAP2+, TH+, and Synaptophysin+ colonies generated by iPSCs derived from human fetal NSCs by one-factor
reprogramming (OCT4, hiPSC
1F-NSC), by iPSCs derived from human fetal NSCs by two-factor reprogramming (OCT4, KLF4; hiPSC2F-NSC),
by iPSCs derived from human fibroblasts by three-factor reprogramming (OCT4, KLF4, and SOX2; hiPSC
3F-FIB), and by iPSCs derived from
human fibroblasts by classical four-factor reprogramming (OCT4, KLF4, SOX2, and c-Myc; hiPSC
4F-FIB) after 3-4 weeks of differentiation on
PA6 stromal cells. Scale bars represent 200 𝜇m. (b) Values are means ± SEM from at least three to four independent experiments. ∗𝑝 < 0.05,
post hoc t-tests with Bonferroni adjustment in comparison to hiPSC
4F-FIB.
adjusted post hoc 𝑡-test was performed to determine differ-
ences between different iPSCs. Results are provided as mean
± standard error of the mean (SEM).
3. Results
To assess fate determination towards neural lineages, colonies
of different iPSC types were immunostained against the
neuronal marker TUJ1, the astroglial marker GFAP, and
the oligodendrocyte marker GALC after 3-4 weeks of
differentiation. As expected, we found high numbers of
TUJ1 colonies in hiPSC
4F-FIB (82 ± 16% of all colonies).
Surprisingly, also factor-reduced hiPSC produced high
amounts of neurons with similar percentages compared to
hiPSC
4F-FIB (hiPSC3F-FIB 59 ± 8%, hiPSC1F-NSC 64 ± 7%, and
hiPSC
2F-NSC 61 ± 4%; 𝑛 = 3-4; 𝐹-value: 2.916, 𝑝 = 0.87;
one-way ANOVA) (Figure 1(b)). No significant differences
were observed in the quantification of the astroglial marker
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GFAP between hiPSC
1F-NSC, 14 ± 11%, and hiPSC2F-NSC,
9 ± 7%; (𝑝 = 0.574, two-sided unpaired 𝑡-test; Figure 1(b)).
For GALC+ oligodendrocytes we found significantly reduced
numbers of positive colonies in hiPSC
3F-FIB compared to
hiPSC
1F-NSC (𝑝 = 0.047, post hoc two-sided 𝑡-test with
Bonferroni adjustment; one-wayANOVA;𝐹-value: 5.557;𝑝 =
0.036) but not to hiPSC
2F-NSC (𝑝 = 0.114; post hoc Bonferroni
𝑡-test; hiPSC
1F-NSC 38 ± 10%, hiPSC2F-NSC 35 ± 2%, and
hiPSC
3F-FIB 17 ± 7%).
Quantification of MAP2, a marker for mature neurons,
revealed similar proportions of MAP2+ colonies in clas-
sical fibroblast-derived hiPSCs (hiPSC
4F-FIB 63 ± 10% of
all colonies) compared to factor-reduced fibroblast-derived
hiPSCs (hiPSC
3F-FIB 60 ± 17%) and NSC-derived hiPSCs
(hiPSC
1F-NSC 33±7% and hiPSC2F-NSC 47±16%); (𝐹-value =
3.385, 𝑝 = 0.062, one-way ANOVA). Synaptophysin was used
as a marker for fully mature neurons indicating the presence
of functional synapses. Factor reduction led to a significant
reduction of Synaptophysin positive colonies in hiPSC
3F-FIB
(11 ± 4%) compared to hiPSC
4F-FIB (63 ± 18%; 𝐹-value =
7.158, 𝑝 = 0.009, one-way ANOVA; 𝑝 = 0.01; post hoc
Bonferroni 𝑡-test) but not when compared to factor-reduced
NSC-derived hiPSCs (hiPSC
1F-NSC 27 ± 7%, 𝑝 = 0.078; and
hiPSC
2F-NSC 38 ± 15%, 𝑝 = 0.363; both post hoc Bonferroni
𝑡-test).
Exemplarily, dopaminergic neuronal differentiation was
investigated which would be of interest for Parkinson’s dis-
ease. Colonies were quantified for presence of the marker
protein tyrosine hydroxylase (TH) (Figure 1). 56 ± 6% TH-
positive colonies were present after differentiation of classical
fibroblast-derived hiPSC with no significant difference to
factor-reduced fibroblast-derived hiPSC, hiPSC
3F-FIB (54 ±
11%), and to NSC-derived hiPSCs (hiPSC
1F-NSC 43 ± 9% and
hiPSC
2F-NSC 50 ± 5%; 𝐹-value = 1.599, 𝑝 = 0.251, one-way
ANOVA; Figure 1(b)).
4. Discussion
An approach tominimize the risk for insertionalmutagenesis
and to simplify the reprogramming process in pluripotent
stem cell research is the reduction of reprogramming factors
[24–33]. Until recently, studies on factor-reduced human
iPSC mainly focused on the derivation of individual iPSC
clones without investigating their differentiation potential in
detail. This, however, is of great importance when discussing
possible clinical applications. The take-home message of the
current study is that in contrast to murine factor-reduced
iPSCs human NSC-derived factor-reduced iPSCs retain the
full neuroectodermal differentiation potential. This is of
major interest since this would allow factor reduction as an
attempt to decrease the risk of malignancy after transplan-
tation in humans. A combination of factor reduction and
the use of protein reprogramming could be a significant step
towards clinical application.
One major limitation of the factor reduction is the
significantly decreased efficiency in iPSC generation. This
also limits our study since only very few clones could
be investigated. Nevertheless, these few clones showed a
neuronal differentiation behaviour comparable not only to
ESC and iPSC differentiation [34, 37] but also to mouse, rat,
and human NSC differentiation [39–42].
The differences to our previous results of factor-reduced
mouse iPSCs [34] could be versatile. Species to species
differences are always possible. The factor-reduced mouse
iPSCs were derived from postnatal NSCs, whereas the factor-
reduced human iPSCs mentioned here were derived from
fetal humanNSCs.We cannot exclude the fact that this devel-
opmental difference could be a relevant factor influencing the
postreprogramming differentiation capacity. Further studies
like performing these experiments with factor-reduced iPSCs
derived from adult humanNSCs are warranted. Additionally,
it would be interesting to investigate iPSCs derived from fetal
human fibroblasts. Finally, one major difference is, however,
the details of the proof of pluripotency in the different
systems. In murine iPSC, generation of chimeras, germline
transmission, and tetraploid embryo aggregation is the most
compelling proof of pluripotency. These tests are obviously
not possible with human iPSCs. Thus, one cannot fully rule
out the fact that human iPSCs are not 100% reprogrammed
and thus the different clones may vary more than in the
murine system. Additionally, classical reprogramming could
also lead to intermediates [43] as well as induced NSCs
[43, 44]. This is, however, unlikely since all our iPSCs used
here bear the differentiation potential into all germ layers
[32, 35, 36]. A recent study by Hu et al. suggested that neural
differentiation of iPSCs derived fromhumanfibroblasts is less
efficient and more variable across cell lines than in ESC [45].
This was shown to be independent from the technique used
for reprogramming.This, however, makes it difficult to iden-
tify which contributorsmay have had an influence on the effi-
ciency of neural differentiation in the individual iPSCs [45].
Another debate is about the protocol for neuronal differ-
entiation we used within this study. We chose this protocol
since it avoids an intermediate step of NSC propagation in
which the potential well-behavingNSC subpopulations could
overgrow not well differentiating ones, thereby masking
potential differences in the neuroectodermal differentiation
[46]. This is, however, on the cost of dealing with a coculture
system with significant limitations concerning cell character-
izations.
Nevertheless, since we herein prove the noninferiority of
the neuroectodermal differentiation capacity of the human
factor-reduced iPSCs and the differentiation capacity was
well within the known range [37], we believe that human
factor-reduced iPSCs behave similar to classical iPSCs and
thus might be more suitable for clinical application in the
future.
5. Conclusion
We herein show that, in contrast to murine factor-reduced
iPSCs, human NSC-derived factor-reduced iPSCs retain the
full neuroectodermal differentiation potential. This is of
major interest since this would allow factor reduction as an
attempt to decrease the risk for malignancy after transplan-
tation in humans. A combination of factor reduction and
the use of protein reprogramming could be a significant step
towards clinical application.
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to provision of study material, critical revision of the paper,
and fund raising. Alexander Storch contributed to conception
and design, data analysis and interpretation, drafting and
critical revision of the paper, and fund raising.
Acknowledgments
The authors would like to thank Sylvia Kanzler for her
excellent technical assistance. This work was supported by
the Bundesministerium für Bildung und Forschung (research
program “Gewinnung pluri- bzw. multipotenter Stam-
mzellen”; AZ: 01GN1006C) to Alexander Storch, Andreas
Hermann, and Hans R. Schöler and by the Helmholtz
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